BUZZ-TD Cowen lowers its target price for UnitedHealth Group ahead of third-quarter earnings release
路透社2026/10/09 10:31On October 9, TD Cowen lowered its price target for UnitedHealth Group (UNH.N) from $430 to $402 ahead of the company's third-quarter earnings report on October 13. The brokerage stated that the widely expected third-quarter medical cost ratio of 89.9% and earnings per share of $4.12 are "well within reach." The report pointed out that recently announced Medicare star ratings have fallen as anticipated, which is expected to create a $1.5 billion revenue headwind in 2028. The new price target represents a 6.9% upside from the stock's previous closing price. "We also expect management to comment on preliminary expectations for 2027 Medicare Advantage (MA) enrollment growth and may emphasize a focus on margins over enrollment growth," the brokerage added. Earnings forecasts remain unchanged, but a lowered valuation multiple led to the reduction in price target. Among 29 brokerages, 23 rate the stock a "buy" or higher, while 6 rate it "hold"; the median price target is $483.82, according to LSEG data. As of the previous close, the stock is up 12.3% year-to-date.
October 9 - ** TD Cowen, ahead of UnitedHealth Group's UNH.N third quarter earnings release on October 13, lowered its price target from $430 to $402
** The brokerage stated that the market consensus for the third quarter medical loss ratio is 89.9%, and EPS is $4.12, both of which are “fully achievable”
** The report pointed out that (link) the recently published Medicare star ratings declined as expected, which is projected to create a revenue headwind of $1.5 billion in 2028
** The new price target is 6.9% above the previous trading day's closing price
** “We also expect management to mention preliminary expectations for Medicare Advantage (MA) membership growth for 2027, and may stress a focus on margins rather than member growth,” the brokerage added
** Earnings forecasts remain unchanged, but a lower valuation multiple led to the reduced price target
** Of 29 brokerages, 23 rate the stock as “buy” or higher, and six as “hold”; median price target is $483.82 — LSEG data
** As of the previous trading day's close, the stock is up 12.3% year-to-date
(To assist non-English speakers, Reuters provides automated translation of its reports into a number of other languages. As automated translation may contain errors or may not include the required context, Reuters does not guarantee the accuracy of automated translation. Automated translation is provided for reader convenience only. Reuters is not liable for any damage or loss caused by use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Leerink says concerns over growth in the medical technology sector may overshadow third-quarter performance
October 9 – Leerink Partners stated that, ahead of the third-quarter earnings reports, it remains cautious on the medical technology sector and pointed out that the short-term market environment is “somewhat uncertain.” The firm noted increasing competition in some markets, including the cardiac devices and diabetes care sectors; uncertainty in surgical volumes amid rising costs; weak consumer confidence; and pressure on hospital budgets due to higher interest rates. “We believe that even if third-quarter results are positive, they may be overshadowed by ongoing market concerns about profitability and growth prospects for 2027 and beyond,” the broker said. The firm believes that positive factors for specific companies could help Medtronic (MDT.N) and Tandem Diabetes Care (TNDM.O) outperform the broader industry during these sector-wide headwinds. The broker said it remains most cautious on PROCEPT BioRobotics (PRCT.O) and Insulet (PODD.O), as a slowdown in adoption and intensifying competition may lead to lowered expectations for 2027. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or fail to capture the required context, Reuters does not guarantee the accuracy of automated translation texts, and they are provided merely for readers’ convenience. Reuters accepts no liability for any damage or loss resulting from the use of automated translation features.)
EUR/USD Price Forecast: Rallies fail above 1.1200 amid high Oil prices, debt woes
The strongest growth outlook in over two years is approaching! US medical device stocks still need to endure another sluggish earnings season
The third-quarter profit growth of medical device companies is expected to be only 4.8%, but it is projected to accelerate to 13% in the first quarter of next year, marking the strongest performance in over two years. However, policy uncertainties and product recalls have dampened confidence, and the market is awaiting a recovery by 2027.
BUZZ—US Stock Market Dynamics: SpaceX, Humana, Delta Air Lines
Workspace search string for querying individual stock trends: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Brief": https://refini.tv/3dKUyB8 Reuters, October 9 — On Friday, U.S. stock index futures rose as oil prices retreated due to easing concerns over Middle East supply. However, telecom stocks remained under pressure as SpaceX's acquisition of spectrum sparked competition concerns across the telecom sector. - **T-Mobile US Inc (TMUS.O):** Hot topic — European telecom stocks fell after the SpaceX spectrum deal. [nL6N45V0EH] - **Space Exploration Technologies Corp (SPCX.O):** Hot topic — Shares rose after reaching an agreement to acquire a nationwide low-band spectrum portfolio. [nL4N45V0KP] - **Humana Inc (HUM.N):** Hot topic — Shares rose after its “Medicare Advantage” rating was raised. [nL4N45V0LU] - **Definium Therapeutics Inc (DFTX.O):** Market buzz — Shares increased after JPMorgan gave its LSD-based therapy an “Overweight” rating. [nL4N45V0NH] - **UnitedHealth Group Inc (UNH.N):** Market movement — TD Cowen lowered its target price ahead of UnitedHealth’s Q3 financial report. [nL4N45V0OU] - **Newmont Corporation (NEM.N):** - **Gold Fields Ltd (GFI.N):** - **Harmony Gold Mining Company Limited (HMY.N):** - **AngloGold Ashanti Ltd (AU.N):** Market movement — Gold miners’ shares rose in line with a slight rise in gold prices driven by a weaker dollar. [nL4N45V0PG] - **Delta Air Lines Inc (DAL.N):** Market flash — Shares fell after sharply lowering full-year profit forecast. [nL4N45V0RA] - **Apple Inc (AAPL.O):** Hot topic — Shares declined amid reports of iPhone production cuts. [nL4N45V0SB] - **Crescent Energy Company (CRGY.N):** Hot topic — Shares fell after raising 1 billion USD to acquire Devon Energy. [nL6N45V0J4] (For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. As automated translations may contain errors or may not capture the necessary context, Reuters does not guarantee the accuracy of the automated translation text, which is provided solely for readers’ convenience. Reuters accepts no liability for any damage or loss caused by the use of this function.)
Crypto prices
More
